Production of [F]DPA-714, [F]fallypride and [F]LBT-999 using iMiDEV, a fully automated microfluidic platform: towards clinical radiopharmaceutical production.

Background: Positron emission tomography is widely used to study biological processes without disrupting normal physiological functions. Traditional radiotracer synthesis and industrial market is focused on producing large batches of F-labelled tracers, especially [F]FDG. Accessibility to smaller quantity of diverse radiopharmaceuticals is a key to enable a more personalised approach in nuclear medicine.

Microfluidic-based production of [Ga]Ga-FAPI-46 and [Ga]Ga-DOTA-TOC using the cassette-based iMiDEV™ microfluidic radiosynthesizer.

Background: The demand for Ga-labeled radiotracers has significantly increased in the past decade, driven by the development of diversified imaging tracers, such as FAPI derivatives, PSMA-11, DOTA-TOC, and DOTA-TATE. These tracers have exhibited promising results in theranostic applications, fueling interest in exploring them for clinical use. Among these probes, Ga-labeled FAPI-46 and DOTA-TOC have emerged as key players due to their ability to diagnose a broad spectrum of cancers ([Ga]Ga-FAPI-46) in late-phase studies, whereas [Ga]Ga-DOTA-TOC is clinically approved for neuroendocrine tumors.